Hüseyin TOL, Hüseyin ATALAY, İBRAHİM GÜNEY, Hakkı GÖKBEL, Lütfullah ALTINTEPE, Sadık BÜYÜKBAŞ, Said BODUR, NEDİM YILMAZ SELÇUK, Halil Zeki TONBUL, Mehdi YEKSAN, Süleyman TÜRK

The effects of gabapentin therapy on pruritus, quality of life, depression and sleep quality in pruritic hemodialysis patients

Amaç: Gabapentin tedavisi ile kaşıntı şikayeti olan hemodiyaliz (HD) hastalarında kaşıntı, yaşam kalitesi, depresyon ve uyku kalitesindeki olası değişiklikleri tespit etmeyi amaçladık. Hastalar ve Yöntemler: Sekiz haftadan daha uzun süreli kaşıntı öyküsü olan 14 HD hastasına (7 erkek, 7 kadın; ort. yaş 59.7±17.2; dağılım 41-88) günde 300 mg gabapentin 8 hafta süre ile verildi. Çalışma öncesi 1 hafta, aktif tedavi fazı, plasebo fazı ve araya giren 1 haftalık temizlenme fazı esnasında görsel analog ölçeği kullanılarak günlük kaşıntı skorları kaydedildi. Uyku kalitesi modifiye uyku-sonrası kaydı ile, yaşam kalitesi Tıbbi Sonuç Çalışması Kısa Form-36 şekli (SF-36) ile ve depresyon da Beck Depresyon kaydı kullanılarak değerlendirildi. Bulgular: Gabapentin tedavisi ile ortalama kaşıntı skorunda ve toplam uyku-sonrası kaydı skorunda anlamlı derecede düşüş gözlendi (sırasıyla p=0.01 ve p=0.002). SF-36'nın fiziksel ve mental komponent skorları gabapentin tedavisi ile artarken, bilişsel ve somatik depresyon indeksleri gabapentin ile azaldı. Sonuç: Gabapentin tedavisi kaşıntı şikayeti olan hemodiyaliz hastalarında kaşıntı, yaşam kalitesi, depresyon ve uyku kalitesi üzerinde klinik olarak önemli yararlı etkilere sahiptir. Gabapentin tedavisi kaşıntısı olan hemodiyaliz hastalarında önemli bir tedavi seçeneği olarak göz önünde bulundurulmalıdır.

Kaşıntılı hemodiyaliz hastalarında gabapentin tedavisinin kaşıntı, yaşam kalitesi, depresyon ve uyku kalitesine etkisi

Objectives: We aimed to determine possible changes in pruritus, quality of life, depression and sleep quality in pruritic hemodialysis (HD) patients with gabapentin therapy. Patients and Methods: Fourteen adult HD patients (7 men, 7 women; mean age 59.7±17.2 years; range 41 to 88 years) with history of pruritus of more than eight weeks were assigned to receive 8-week gabapentin (300 mg per day) therapy. The daily pruritus were recorded using visual analogue scale for each period of the study during one week preceding the trial, the active treatment phase, the placebo phase and the intervening 1-week washout period. Sleep quality was determined with a modified post-sleep inventory, quality of life with a short form of Medical Outcomes Study (SF-36), depression using the Beck Depression Inventory. Results: The mean pruritus score and total of post-sleep inventory were decreased significantly with gabapentin therapy (p=0.01 and p=0.002 respectively). Physical and mental component scales of SF-36 increased, whereas cognitive and somatic depression index decreased with gabapentin. Conclusion: We concluded that beneficial effects of gabapentin therapy on pruritus, quality of life, depression and sleep quality are clinically important in HD patients with pruritus. Gabapentin therapy should be taken into account as an important choice of therapy in pruritic HD patients.

PDF

___

1) Chargin L, Keil H. Skin diseases in nonsurgical renal disease. Arch Derm Syphilol 1932;26:314-35.
2) Parfrey PS, Vavasour HM, Henry S, Bullock M, Gault MH. Clinical features and severity of nonspecific symptoms in dialysis patients. Nephron 1988;50:121-8.
3) Watnick S, Kirwin P, Mahnensmith R, Concato J. The prevalence and treatment of depression among patients starting dialysis. Am J Kidney Dis 2003;41:105-10.
4) Türk S, Guney I, Altintepe L, Tonbul Z, Yildiz A, Yeksan M. Quality of life in male hemodialysis patients. Role of erectile dysfunction. Nephron Clin Pract 2004;96:c21-7.
5) Rose MA, Kam PC. Gabapentin: pharmacology and its use in pain management. Anaesthesia 2002;57:451-62.
6) Webb WB, Bonnet M, Nlume G. A post-sleep inventory. Percept Mot Skills 1976;43:987-93.
7) Veiga J, Goncalves N, Gomes F, Santos N, Baptista A, Paiva T. Sleep disturbances in end-stage renal disease patients on hemodialysis. Dial Transplant 1997;26:380-4.
8) Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
9) Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey manual and interpretation guide. Boston, MA: New England Medical Center, The Health Institute; 1993.
10) Ware JE Jr, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care 1995;33(4 Suppl):AS264-79.
11) Johansen KL, Painter P, Kent-Braun JA, Ng AV, Carey S, Da Silva M, et al. Validation of questionnaires to estimate physical activity and functioning in end-stage renal disease. Kidney Int 2001;59:1121-7.
12) Craven JL, Rodin GM, Littlefield C. The Beck Depression Inventory as a screening device for major depression in renal dialysis patients. Int J Psychiatry Med 1988;18:365-74.
13) Kimmel PL, Peterson RA, Weihs KL, Simmens SJ, Alleyne S, Cruz I, et al. Multiple measurements of depression predict mortality in a longitudinal study of chronic hemodialysis outpatients. Kidney Int 2000;57:2093-8.
14) Zakrzewska-Pniewska B, Jedras M. Is pruritus in chronic uremic patients related to peripheral somatic and autonomic neuropathy? Study by R-R interval variation test (RRIV) and by sympathetic skin response (SSR). Neurophysiol Clin 2001;31:181-93.
15) Johansson O, Hilliges M, Ståhle-Bäckdahl M. Intraepidermal neuron-specific enolase (NSE)-immunoreactive nerve fibres: evidence for sprouting in uremic patients on maintenance hemodialysis. Neurosci Lett 1989;99:281-6.
16) Weisshaar E, Dunker N, Gollnick H. Topical capsaicin therapy in humans with hemodialysis-related pruritus. Neurosci Lett 2003;345:192-4.
17) Mettang T, Pauli-Magnus C, Alscher DM. Uraemic pruritus--new perspectives and insights from recent trials. Nephrol Dial Transplant 2002;17:1558-63.
18) Morton CA, Lafferty M, Hau C, Henderson I, Jones M, Lowe JG. Pruritus and skin hydration during dialysis. Nephrol Dial Transplant 1996;11:2031-6.
19) Peer G, Kivity S, Agami O, Fireman E, Silverberg D, Blum M, et al. Randomised crossover trial of naltrexone in uraemic pruritus. Lancet 1996;348:1552-4.
20) Urbonas A, Schwartz RA, Szepietowski JC. Uremic pruritus--an update. Am J Nephrol 2001;21:343-50.
21) Arıcan Ö. Kaşıntının patofizyolojisi, kliniği ve tedavisi. Turkderm 2005;39:88-97.
22) Fusaro M, Munaretto G, Spinello M, Gallieni M. Regression of uraemic pruritus by cyclosporin treatment in a haemodialysis patient. Nephrol Dial Transplant 2004;19:1338-9.
23) Gunal AI, Ozalp G, Yoldas TK, Gunal SY, Kirciman E, Celiker H. Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrol Dial Transplant 2004;19:3137-9.
24) Manenti L, Vaglio A, Costantino E, Danisi D, Oliva B, Pini S, et al. Gabapentin in the treatment of uremic itch: an index case and a pilot evaluation. J Nephrol 2005;18:86-91.
25) Finkelstein FO, Finkelstein SH. Psychological adaptation and quality of life of the patient with end-stage renal disease. In: Brown EA, Parfrey P, editors. Complications of long-term dialysis. London: Oxford University Press; 1999. p. 170-92.
26) Young LT, Robb JC, Patelis-Siotis I, MacDonald C, Joffe RT. Acute treatment of bipolar depression with gabapentin. Biol Psychiatry 1997;42:851-3.
27) Wang PW, Santosa C, Schumacher M, Winsberg ME, Strong C, Ketter TA. Gabapentin augmentation therapy in bipolar depression. Bipolar Disord 2002;4:296-301.
28) Walters BA, Hays RD, Spritzer KL, Fridman M, Carter WB. Health-related quality of life, depressive symptoms, anemia, and malnutrition at hemodialysis initiation. Am J Kidney Dis 2002;40:1185-94.
29) Rodrigues JP, Edwards DJ, Walters SE, Byrnes ML, Thickbroom G, Stell R, et al. Gabapentin can improve postural stability and quality of life in primary orthostatic tremor. Mov Disord 2005;20:865-70.